One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Krzysztof Myrda, Mariusz Gąsior, Dariusz Dudek, Bartłomiej Nawrotek, Jacek Niedziela, Wojciech Wojakowski, Marek Gierlotka, Marek Grygier, Janina Stępińska, Adam Witkowski, Maciej Lesiak, Jacek Legutko
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	acute coronary syndrome cardiogenic shock glycoprotein IIb/IIIa receptor inhibitors myocardial infarction percutaneous coronary intervention Medicine R
Acceso en línea:	https://doaj.org/article/055c513894134979920c6611399ed8a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:055c513894134979920c6611399ed8a0
record_format	dspace
spelling	oai:doaj.org-article:055c513894134979920c6611399ed8a02021-11-11T17:40:54ZOne-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock10.3390/jcm102150592077-0383https://doaj.org/article/055c513894134979920c6611399ed8a02021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5059https://doaj.org/toc/2077-0383Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required inotropes and intra-aortic balloon pump (IABP) support more frequently, and showed a lower efficacy of coronary angioplasty. In both groups, the same rates of in-hospital adverse events were observed. A lower mortality rate was reported in the group treated with GPIs 12 months after admission (54.9% vs. 57.9%, <i>p</i> = 0.002). Therapy with GPI was an independent factor reducing the risk of mortality in the 12-month follow-up. Conclusions: The addition of GPIs to the standard pharmacotherapy combined with PCI in patients with MI and CS on admission reduced the risk of death in the 12-month follow-up period without increasing in-hospital adverse event rates.Krzysztof MyrdaMariusz GąsiorDariusz DudekBartłomiej NawrotekJacek NiedzielaWojciech WojakowskiMarek GierlotkaMarek GrygierJanina StępińskaAdam WitkowskiMaciej LesiakJacek LegutkoMDPI AGarticleacute coronary syndromecardiogenic shockglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionpercutaneous coronary interventionMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5059, p 5059 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute coronary syndrome cardiogenic shock glycoprotein IIb/IIIa receptor inhibitors myocardial infarction percutaneous coronary intervention Medicine R
spellingShingle	acute coronary syndrome cardiogenic shock glycoprotein IIb/IIIa receptor inhibitors myocardial infarction percutaneous coronary intervention Medicine R Krzysztof Myrda Mariusz Gąsior Dariusz Dudek Bartłomiej Nawrotek Jacek Niedziela Wojciech Wojakowski Marek Gierlotka Marek Grygier Janina Stępińska Adam Witkowski Maciej Lesiak Jacek Legutko One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
description	Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required inotropes and intra-aortic balloon pump (IABP) support more frequently, and showed a lower efficacy of coronary angioplasty. In both groups, the same rates of in-hospital adverse events were observed. A lower mortality rate was reported in the group treated with GPIs 12 months after admission (54.9% vs. 57.9%, <i>p</i> = 0.002). Therapy with GPI was an independent factor reducing the risk of mortality in the 12-month follow-up. Conclusions: The addition of GPIs to the standard pharmacotherapy combined with PCI in patients with MI and CS on admission reduced the risk of death in the 12-month follow-up period without increasing in-hospital adverse event rates.
format	article
author	Krzysztof Myrda Mariusz Gąsior Dariusz Dudek Bartłomiej Nawrotek Jacek Niedziela Wojciech Wojakowski Marek Gierlotka Marek Grygier Janina Stępińska Adam Witkowski Maciej Lesiak Jacek Legutko
author_facet	Krzysztof Myrda Mariusz Gąsior Dariusz Dudek Bartłomiej Nawrotek Jacek Niedziela Wojciech Wojakowski Marek Gierlotka Marek Grygier Janina Stępińska Adam Witkowski Maciej Lesiak Jacek Legutko
author_sort	Krzysztof Myrda
title	One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
title_short	One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
title_full	One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
title_fullStr	One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
title_full_unstemmed	One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
title_sort	one-year outcome of glycoprotein iib/iiia inhibitor therapy in patients with myocardial infarction-related cardiogenic shock
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/055c513894134979920c6611399ed8a0
work_keys_str_mv	AT krzysztofmyrda oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT mariuszgasior oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT dariuszdudek oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT bartłomiejnawrotek oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT jacekniedziela oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT wojciechwojakowski oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT marekgierlotka oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT marekgrygier oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT janinastepinska oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT adamwitkowski oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT maciejlesiak oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock AT jaceklegutko oneyearoutcomeofglycoproteiniibiiiainhibitortherapyinpatientswithmyocardialinfarctionrelatedcardiogenicshock
_version_	1718431982040383488

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

Ejemplares similares